BIXT fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. Its product pipeline includes BXT-25, a drug designed to oxygenate ischemic (reduced blood flow) regions in the brain that suffered from hypoxia during a brain stroke, and BXT-252, which treats chronic wounds resulting from ischemia caused by occlusion of capillaries. The company was founded on June 9, 2008 and is headquartered in Needham, MA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
BIXT does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company